Inversago Pharma picks up $35m in Forbion-led Series B

Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this